<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39334184</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2458</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC public health</Title><ISOAbbreviation>BMC Public Health</ISOAbbreviation></Journal><ArticleTitle>Examining changes in pain interference via pandemic-induced isolation among patients receiving medication for opioid use disorder: a secondary data analysis.</ArticleTitle><Pagination><StartPage>2581</StartPage><MedlinePgn>2581</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2581</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12889-024-20077-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Early in the pandemic, the United States population experienced a sharp rise in the prevalence rates of opioid use, social isolation, and pain interference. Given the high rates of pain reported by patients on medication for opioid use disorder (MOUD), the pandemic presented a unique opportunity to disentangle the relationship between opioid use, pain, and social isolation in this high-risk population. We tested the hypothesis that pandemic-induced isolation would partially mediate change in pain interference levels experienced by patients on MOUD, even when controlling for baseline opioid use. Such work can inform the development of targeted interventions for a vulnerable, underserved population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Analyses used data from a cluster randomized trial (N = 188) of patients on MOUD across eight opioid treatment programs. As part of the parent trial, participants provided pre-pandemic data on pain interference, opioid use, and socio-demographic variables. Research staff re-contacted participants between May and June 2020 and 133 participants (71% response rate) consented to complete a supplemental survey that assessed pandemic-induced isolation. Participants then completed a follow-up interview during the pandemic that again assessed pain interference and opioid use. A path model assessed whether pre-pandemic pain interference had an indirect effect on pain interference during the pandemic via pandemic-induced isolation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Consistent with hypotheses, we found evidence that pandemic-induced isolation partially mediated change in pain interference levels among MOUD patients during the pandemic. Higher levels of pre-pandemic pain interference and opioid use were both significantly associated with higher levels of pandemic-induced isolation. In addition, pre-pandemic pain interference was significantly related to levels of pain interference during the pandemic, and these pain levels were partially explained by the level of pandemic-induced isolation reported.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients on MOUD with higher use of opioids and higher rates of pain pre-pandemic were more likely to report feeling isolated during COVID-related social distancing and this, in turn, partially explained changes in levels of pain interference. These results highlight social isolation as a key risk factor for patients on MOUD and suggest that interventions promoting social connection could be associated with reduced pain interference, which in turn could improve patient quality of life.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT03931174 (Registered 04/30/2019).</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frohe</LastName><ForeName>Tessa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, School of Medicine, University of Washington, 1959 NE Pacific ST, Box 357238, Seattle, WA, 98195-7238, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssen</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garner</LastName><ForeName>Bryan R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Ohio State University, The Ohio State University College of Medicine, 2050 Kenny Road, Columbus, 43221, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Sara J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Center for Dissemination and Implementation Science, Northwestern University Feinberg School of Medicine, 633 North St Clair, Suite 2000, Chicago, IL, USA. sara.becker@northwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03931174</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K01 AA030053</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AA026335</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01AA030053 (PI: Frohe)</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA046941</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DA046941 (PIs: Becker &amp; Garner)</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01AA026335 (PI: Janssen)</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Public Health</MedlineTA><NlmUniqueID>100968562</NlmUniqueID><ISSNLinking>1471-2458</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Res Sq. 2023 Aug 09:rs.3.rs-3158420. doi: 10.21203/rs.3.rs-3158420/v1</RefSource><PMID Version="1">37609151</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009293" MajorTopicYN="Y">Opioid-Related Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012934" MajorTopicYN="Y">Social Isolation</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078332" MajorTopicYN="N">Data Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094422" MajorTopicYN="N">Secondary Data Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Medication for opioid use disorder</Keyword><Keyword MajorTopicYN="N">Opioid treatment program</Keyword><Keyword MajorTopicYN="N">Pain</Keyword><Keyword MajorTopicYN="N">Pandemic</Keyword><Keyword MajorTopicYN="N">Social isolation</Keyword><Keyword MajorTopicYN="N">Substance use</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39334184</ArticleId><ArticleId IdType="pmc">PMC11428855</ArticleId><ArticleId IdType="doi">10.1186/s12889-024-20077-9</ArticleId><ArticleId IdType="pii">10.1186/s12889-024-20077-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spencer MR, Miniño AM, Warner M. Drug overdose deaths in the United States, 2001–2021. NCHS Data Brief. 2022;457:1–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">36598401</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488216</ArticleId><ArticleId IdType="pubmed">32929211</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkow N. New evidence on substance use disorders and COVID-19 susceptibility. NIDA Available online: https://www.drugabusegov/about-nida/noras-blog/2020/10/new-evidence-substance-use-disorders-COVID-19-susceptibility (accessed on February 3, 2021). 2020.</Citation></Reference><Reference><Citation>Siegel Z. The Deadliest Year In the History of U.S. Drug Use. New York Intelligencer. 2020.</Citation></Reference><Reference><Citation>Wan W, Long H. ‘Cries for help’: Drug overdoses are soaring during the coronavirus pandemic. Wash Post. 2020, July 1.</Citation></Reference><Reference><Citation>CDC, – 00438 HANA, Health Alert Network (HAN). Increase in Fatal Drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. Centers Disease Control Prev. 2020, December 17 https://emergency.cdc.gov/han/2020/han00438.asp</Citation></Reference><Reference><Citation>Koopmann A, Georgiadou E, Kiefer F, Hillemacher T. Did the general population in Germany drink more alcohol during the COVID-19 pandemic lockdown? Alcohol Alcohol. 2020;55(6):698–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337704</ArticleId><ArticleId IdType="pubmed">32556079</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhee MD, Keough MT, Rundle S, Heath LM, Wardell JD, Hendershot CS. Depression, environmental reward, coping motives and alcohol consumption during the COVID-19 pandemic. Front Psychiatry. 2020;11:574676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7661794</ArticleId><ArticleId IdType="pubmed">33192708</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson E, Gillespie S, Jones A. Weight-related lifestyle behaviours and the COVID‐19 crisis: an online survey study of UK adults during social lockdown. Obes Sci Pract. 2020;6(6):735–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746963</ArticleId><ArticleId IdType="pubmed">33354349</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanton R, To QG, Khalesi S, Williams SL, Alley SJ, Thwaite TL, et al. Depression, anxiety and stress during COVID-19: associations with changes in physical activity, sleep, tobacco and alcohol use in Australian adults. Int J Environ Res Public Health. 2020;17(11):4065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7312903</ArticleId><ArticleId IdType="pubmed">32517294</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Li Y, Bao Y, Meng S, Sun Y, Schumann G, et al. Brief report: increased addictive internet and substance use behavior during the COVID-19 pandemic in China. Am J Addictions. 2020;29(4):268–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300868</ArticleId><ArticleId IdType="pubmed">32500608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedson J, Chen Y, Ashworth J, Hayward RA, Dunn KM, Jordan KP. Risk of adverse events in patients prescribed long-term opioids: a cohort study in the UK clinical practice research Datalink. Eur J Pain. 2019;23(5):908–22.</Citation><ArticleIdList><ArticleId IdType="pubmed">30620116</ArticleId></ArticleIdList></Reference><Reference><Citation>Groenewald CB, Law EF, Fisher E, Beals-Erickson SE, Palermo TM. Associations between adolescent chronic pain and prescription opioid misuse in adulthood. J pain. 2019;20(1):28–37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309740</ArticleId><ArticleId IdType="pubmed">30098405</ArticleId></ArticleIdList></Reference><Reference><Citation>Serdarevic M, Gurka KK, Striley CW, Vaddiparti K, Cottler LB. Prevalence of concurrent prescription opioid and hazardous alcohol use among older women: results from a cross-sectional study of community members. J Community Health. 2019;44:172–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7063756</ArticleId><ArticleId IdType="pubmed">30145703</ArticleId></ArticleIdList></Reference><Reference><Citation>Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, Van Der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569–76.</Citation><ArticleIdList><ArticleId IdType="pubmed">25785523</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamison RN, Kauffman J, Katz NP. Characteristics of Methadone Maintenance Patients with Chronic Pain. J Pain Symptom Manag. 2000;19(1):53–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">10687327</ArticleId></ArticleIdList></Reference><Reference><Citation>Arout CA, Waters AJ, MacLean RR, Compton P, Sofuoglu M. Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients. Psychopharmacology. 2019;236:2857–66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6581631</ArticleId><ArticleId IdType="pubmed">30564869</ArticleId></ArticleIdList></Reference><Reference><Citation>Karayannis NV, Baumann I, Sturgeon JA, Melloh M, Mackey SC. The impact of social isolation on pain interference: a longitudinal study. Ann Behav Med. 2019;53(1):65–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6301311</ArticleId><ArticleId IdType="pubmed">29668841</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina BG, Worley MJ. Effects of craving on opioid use are attenuated after pain coping counseling in adults with chronic pain and prescription opioid addiction. J Consult Clin Psychol. 2019;87(10):918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7039171</ArticleId><ArticleId IdType="pubmed">31556668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson E, Zale E, Ditre J, Wesolowicz D, Stennett B, Robinson M, et al. CANUE: a theoretical model of pain as an antecedent for substance use. Ann Behav Med. 2021;55(5):489–502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8122475</ArticleId><ArticleId IdType="pubmed">32914834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturgeon JA, Zautra AJ. Social pain and physical pain: shared paths to resilience. Pain Manage. 2016;6(1):63–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869967</ArticleId><ArticleId IdType="pubmed">26678402</ArticleId></ArticleIdList></Reference><Reference><Citation>Wade JB, Dougherty LM, Archer CR, Price DD. Assessing the stages of pain processing: a multivariate analytical approach. Pain. 1996;68(1):157–67.</Citation><ArticleIdList><ArticleId IdType="pubmed">9252011</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkiewitz K, McCallion E, Vowles KE, Kirouac M, Frohe T, Maisto SA, et al. Association between physical pain and alcohol treatment outcomes: the mediating role of negative affect. J Consult Clin Psychol. 2015;83(6):1044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4658287</ArticleId><ArticleId IdType="pubmed">26098375</ArticleId></ArticleIdList></Reference><Reference><Citation>Clauw DJ, Häuser W, Cohen SP, Fitzcharles M-A. Considering the potential for an increase in chronic pain after the COVID-19 pandemic. Pain. 2020;161(8):1694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302093</ArticleId><ArticleId IdType="pubmed">32701829</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallon N, Brown C, Twiddy H, Brian E, Frank B, Nurmikko T, et al. Adverse effects of COVID-19-related lockdown on pain, physical activity and psychological well-being in people with chronic pain. Br J pain. 2021;15(3):357–68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8339954</ArticleId><ArticleId IdType="pubmed">34377461</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Wakaizumi K, Kubota Y, Murayama H, Tabuchi T. Loneliness, social isolation, and pain following the COVID-19 outbreak: data from a nationwide internet survey in Japan. Sci Rep. 2021;11(1):18643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8452720</ArticleId><ArticleId IdType="pubmed">34545110</ArticleId></ArticleIdList></Reference><Reference><Citation>Karos K, McParland JL, Bunzli S, Devan H, Hirsh A, Kapos FP, et al. The social threats of COVID-19 for people with chronic pain. Pain. 2020;161(10):2229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382418</ArticleId><ArticleId IdType="pubmed">32694381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hruschak V, Flowers KM, Azizoddin DR, Jamison RN, Edwards RR, Schreiber KL. Cross-sectional study of psychosocial and pain-related variables among patients with chronic pain during a time of social distancing imposed by the coronavirus disease 2019 pandemic. Pain. 2021;162(2):619–29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808279</ArticleId><ArticleId IdType="pubmed">33230007</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum A. Prevalence and characteristics of Chronic Pain among chemically dependent patients in Methadone maintenance and residential treatment facilities. JAMA. 2003;289(18):2370.</Citation><ArticleIdList><ArticleId IdType="pubmed">12746360</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith JD, Rowan-Szal GA, Roark RR, Simpson DD. Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend. 2000;58(1–2):55–66.</Citation><ArticleIdList><ArticleId IdType="pubmed">10669055</ArticleId></ArticleIdList></Reference><Reference><Citation>Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006;101(11):1546–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">17034434</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolivar HA, Klemperer EM, Coleman SRM, DeSarno M, Skelly JM, Higgins ST. Contingency management for patients receiving medication for opioid use disorder: a systematic review and Meta-analysis. JAMA Psychiatry. 2021;78(10):1092–102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340014</ArticleId><ArticleId IdType="pubmed">34347030</ArticleId></ArticleIdList></Reference><Reference><Citation>Benishek LA, Dugosh KL, Kirby KC, Matejkowski J, Clements NT, Seymour BL, et al. Prize-based contingency management for the treatment of substance abusers: a meta-analysis. Addiction. 2014;109(9):1426–36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4203362</ArticleId><ArticleId IdType="pubmed">24750232</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend. 1996;42(1):49–54.</Citation><ArticleIdList><ArticleId IdType="pubmed">8889403</ArticleId></ArticleIdList></Reference><Reference><Citation>Poquet N, Lin C. The brief Pain Inventory (BPI). J Physiother. 2016;62(1):52.</Citation><ArticleIdList><ArticleId IdType="pubmed">26303366</ArticleId></ArticleIdList></Reference><Reference><Citation>Felix ED, Binmoeller C, Nylund-Gibson K, Benight CC, Benner AD, Terzieva A. Addressing disaster exposure measurement issues with latent class analysis. J Trauma Stress. 2019;32(1):56–66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386627</ArticleId><ArticleId IdType="pubmed">30698859</ArticleId></ArticleIdList></Reference><Reference><Citation>Muthén LK, Muthén B. Mplus user’s guide: Statistical analysis with latent variables, user’s guide. Muthén &amp; Muthén; 2017.</Citation></Reference><Reference><Citation>MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. A comparison of methods to test mediation and other intervening variable effects. Psychol Methods. 2002;7(1):83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819363</ArticleId><ArticleId IdType="pubmed">11928892</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfons A, Ateş NY, Groenen PJ. A robust bootstrap test for mediation analysis. Organizational Res Methods. 2022;25(3):591–617.</Citation></Reference><Reference><Citation>Office of the Surgeon General (OSG). Our epidemic of loneliness and isolation: The US Surgeon General’s Advisory on the healing effects of social connection and community [Internet]2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">37792968</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy VH. COVID-19 pandemic underscores the need to address social isolation and loneliness. Public Health Rep. 2021;136(6):653–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579386</ArticleId><ArticleId IdType="pubmed">34586920</ArticleId></ArticleIdList></Reference><Reference><Citation>Stubhaug A, Hansen JL, Hallberg S, Gustavsson A, Eggen AE, Nielsen CS. The costs of chronic pain—long-term estimates. Eur J Pain. 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">38214661</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich H. HUNGRY FOR CONNECTION: Library programs are part of a national strategy to combat a major public health epidemic: loneliness. Libr J. 2024;149(2):12–6.</Citation></Reference><Reference><Citation>Cole SW, Kemeny ME, Taylor SE. Social identity and physical health: accelerated HIV progression in rejection-sensitive gay men. J Personal Soc Psychol. 1997;72(2):320.</Citation><ArticleIdList><ArticleId IdType="pubmed">9107003</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ruddere L, Craig KD. Understanding stigma and chronic pain: a-state-of-the-art review. Pain. 2016;157(8):1607–10.</Citation><ArticleIdList><ArticleId IdType="pubmed">26859821</ArticleId></ArticleIdList></Reference><Reference><Citation>Thames AD, Irwin MR, Breen EC, Cole SW. Experienced discrimination and racial differences in leukocyte gene expression. Psychoneuroendocrinology. 2019;106:277–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6589103</ArticleId><ArticleId IdType="pubmed">31029930</ArticleId></ArticleIdList></Reference><Reference><Citation>Earnshaw VA, Smith LR, Chaudoir SR, Amico KR, Copenhaver MM. HIV stigma mechanisms and well-being among PLWH: a test of the HIV stigma framework. AIDS Behav. 2013;17:1785–95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664141</ArticleId><ArticleId IdType="pubmed">23456594</ArticleId></ArticleIdList></Reference><Reference><Citation>Atlam D, Coskunol H. The most severe stigma: Stigma toward substance use disorder. Addicta: Turkish J Addictions. 2022;9(1):99–105.</Citation></Reference><Reference><Citation>Paller CJ, Campbell CM, Edwards RR, Dobs AS. Sex-based differences in pain perception and treatment. Pain Med. 2009;10(2):289–99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745644</ArticleId><ArticleId IdType="pubmed">19207233</ArticleId></ArticleIdList></Reference><Reference><Citation>Polenick CA, Cotton BP, Bryson WC, Birditt KS. Loneliness and illicit opioid use among methadone maintenance treatment patients. Subst Use Misuse. 2019;54(13):2089–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6803066</ArticleId><ArticleId IdType="pubmed">31232142</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson-Genderson M, Heid AR, Cartwright F, Collins AL, Pruchno R. Change in loneliness experienced by older men and women living alone and with others at the onset of the COVID-19 pandemic. Res Aging. 2022;44(5–6):369–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9039590</ArticleId><ArticleId IdType="pubmed">34344251</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Grol-Prokopczyk H, Reid MC, Pillemer K. The Relationship between Pain and Psychological Distress during the COVID-19 pandemic: is Social Technology Use Protective? Pain Med. 2022;23(2):280–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8499956</ArticleId><ArticleId IdType="pubmed">34480572</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell VD, Kumar N, Galecki AT, Kabeto M, Clauw DJ, Williams DA, et al. Bad company: loneliness longitudinally predicts the symptom cluster of pain, fatigue, and depression in older adults. J Am Geriatr Soc. 2022;70(8):2225–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9378441</ArticleId><ArticleId IdType="pubmed">35415848</ArticleId></ArticleIdList></Reference><Reference><Citation>Frohe T, Beseler CL, Mendoza AM, Cottler LB, Leeman RF. Perceived health, medical, and psychiatric conditions in individual and dual-use of marijuana and nonprescription opioids. J Consult Clin Psychol. 2019;87(10):859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764520</ArticleId><ArticleId IdType="pubmed">31556663</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards KA, Vowles KE, McHugh RK, Venner KL, Witkiewitz K. Changes in pain during buprenorphine maintenance treatment among patients with opioid use disorder and chronic pain. J Consult Clin Psychol. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35007092</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondell RD, Ashrafioun L, Dambra CM, Foschio EM, Zielinski AL, Salcedo DM. A clinical trial comparing tapering doses of buprenorphine with steady doses for chronic pain and co-existent opioid addiction. J Addict Med. 2010;4(3):140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2931595</ArticleId><ArticleId IdType="pubmed">20959867</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann AM, Blondell RD, Jaanimägi U, Giambrone AK, Homish GG, Lozano JR, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis. 2013;32(1):68–78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3604999</ArticleId><ArticleId IdType="pubmed">23480249</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>